Comparing CAR T-cell and chemotherapy for cancer treatment
CAR T-cell therapy, a novel immunotherapy modifying patients' T-cells to target cancer cells, shows promising long-lasting remission especially in blood cancers like leukemia and lymphoma, whereas chemotherapy, a widely used drug-based treatment effective across many cancer types but with severe side effects, remains more established, making the choice between them dependent on cancer type, stage, patient health, and treatment response.
The best cancer treatment depends on the type of cancer, the stage of its development, and the health and makeup of the patient. While chemotherapy has remained one of the most common types of cancer treatments, new therapies are also bringing benefits to patients.
One of the most promising cancer treatments is CAR T-cell therapy.
What is CAR T-cell therapy?
CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is a form of immunotherapy that modifies the T-cells of a patient to identify and attack cancer cells selectively. Even though it is a new technology, CAR-T has already shown great promise for treating different types of cancer, including blood cancers such as leukemia and lymphoma.
A clinically effective treatment for these cancers, CAR T-cell therapy has shown the potential to produce long-lasting responses, including complete remission.
What is chemotherapy?
Chemotherapy is one of the most widely known and heavily used cancer treatments. This method uses drugs to kill cancer cells and has long been an effective means to fight cancer.
Chemotherapy, however, has many severe side effects, such as fatigue, hair loss, nausea, and higher infection rates. For this reason, researchers hope to develop other types of cancer treatments that pose less risk and discomfort to patients.
CAR T-cell therapy vs chemotherapy: Which treatment is better?
Determining the most suitable treatment depends on the circumstances of each patient.
- Chemotherapy is a more developed and understood treatment, suitable for a broader range of patients.
- Depending on the cancer type and stage, as well as the success with other treatments, CAR T-cell therapy may be a better option — and it may even be capable of helping patients reach remission.
While every treatment has different advantages and disadvantages, there is no universally correct type of cancer treatment. The most appropriate treatment for a patient will depend on multiple factors, including the type and stage of cancer, overall health, and personal preferences.
Both chemotherapy and CAR-T therapy may be effective treatments for various types of cancer, but they function very differently and pose different risks and benefits.
Related
What is CAR-T therapy or adoptive cell transfer?
CAR T-cell therapy is a cancer treatment that involves modifying a patient’s T cells in the lab to express chimeric antigen receptors (CARs) that enable the T cells to specifically recognize and attack cancer cells, primarily used for certain blood cancers like B cell lymphoma and leukemia, especially when traditional treatments fail or cancer recurs.
When should patients receive CAR T-cell therapy?
CAR T-cell therapy, a potent but costly and time-intensive cancer treatment with significant immune-related side effects, is generally reserved as a last resort for patients with specific cancers like leukemia and lymphoma who have not responded to other therapies or are ineligible for alternative treatments.
FAQ center
The FAQ center explains that lab automation uses data science to create intelligent systems reducing human input, digital labs fully digitize operations for efficiency, future labs will heavily rely on robotics and integrated data management, lab compliance ensures safe and effective lab practices, data integrity ensures reliable data quality, scientific data management systems (SDMS) facilitate safe and accessible scientific data handling, and open data differs from FAIR data in accessibility and usability requirements.
Webinar: Are you Ready for the Renaissance in Small Molecule Drug Discovery?
The webinar titled "Are you Ready for the Renaissance in Small Molecule Drug Discovery?" scheduled for February 2, 2023, features expert Haydn Boehm discussing challenges in small molecule drug discovery, emphasizing the importance of research collaboration, efficient data integration from multiple sources, and workflow optimization to reduce costs and accelerate finding better therapeutic candidates.
How to Apply AI Strategically in Chemistry — Without Repeating Past Mistakes
The article warns against repeating past mistakes in drug discovery by drawing parallels between the failed overreliance on combinatorial chemistry and rigid application of Lipinski’s rules in the early 2000s and the current AI hype, emphasizing the need for strategic, realistic use of AI technologies to avoid inflated expectations, poor-quality compounds, and disillusionment in chemistry.
Webinar: Three Key Considerations When Implementing AI in Drug Discovery
The webinar, led by Haydn Boehm, focuses on three key considerations—reasonable expectations, clean data, and collaboration—for successfully implementing AI in small molecule drug discovery amidst the current hype and ongoing preclinical development of AI-native candidates.